Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AR100DP1
- Development stage
- Unknown
- Lead developer
- Arjil Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
AR100DP1 is a topical ointment formulation of ovatodiolide, a natural macrocyclic diterpenoid originally identified by the Industrial Technology Research Institute (ITRI) and currently under development by Arjil Pharmaceuticals LLC. It functions as an immunomodulator and anti-inflammatory agent, primarily investigated for the treatment of mild to moderate atopic dermatitis. The drug's mechanism of action involves the inhibition of inflammatory pathways, including the NF-kappaB signaling pathway and the NLRP3 inflammasome, which are key drivers of skin inflammation. AR100DP1 received FDA Investigational New Drug (IND) approval in October 2020 and has been evaluated in Phase I/IIa clinical trials (NCT04220411) to determine its safety, tolerability, and efficacy in healthy subjects and patients with atopic dermatitis.
- Other names
- ovatodiolide
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)NF-κB
Beyond the preview
Go deeper on AR100DP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AR100DP1.